MedTrace Logo

OPT101 in Type 1 Diabetes Patients

NCT05428943 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2024-05-03

No results posted yet for this study

Summary

Phase 1b designed to assess safety, pharmacokinetics, immunological and clinical effects of multiple ascending doses of OPT101.

Conditions

  • Diabetes Mellitus, Type 1

Interventions

DRUG

OPT101

15-mer peptide derived from the sequence of mouse CD154.

Sponsors & Collaborators

  • Op-T LLC

    lead INDUSTRY

Principal Investigators

  • Lisa Boswell, MS · OP-T

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-27
Primary Completion
2024-02-21
Completion
2024-02-21
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05428943 on ClinicalTrials.gov